B. John Lindeman Chief Financial Officer CALAVO GROWERS INC 1141-A Cummings Road Santa Paula, CA 93060

Re: CALAVO GROWERS INC

Form 10-K for the Fiscal Year Ended October 31, 2019

Filed December 19, 2019

Form 8-K Filed December 20, 2019

File No. 000-33385

Dear Mr. Lindeman:

We have limited our review of your filing to the financial statements and related

disclosures and have the following comment. In our comment, we may ask you to provide us $% \left(1\right) =\left(1\right) +\left(1\right) +\left$

with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested $% \left(1\right) =\left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left(1\right) +\left(1\right) \left(1\right) \left($

information or advise us as soon as possible when you will respond. If you do not believe our

comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 8-K filed December 20, 2019

Reconciliation of Adjusted Net Income and EPS, page 9

1. Please tell us why your adjustment (a) to eliminate the equity pickup for your investment

in FreshRealm and adjustment (e) which adds back in the losses recorded with respect to

your equity investment in Limoneira do not substitute individually-tailored income or

expense recognition methods for those of GAAP. Refer to Question 100.04

Division's Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

B. John Lindeman

FirstName GROWERS INC Lindeman

CALAVO LastNameB. John

Comapany NameCALAVO GROWERS INC

February 12, 2020

Page 2

February 12, 2020 Page 2

FirstName LastName

In closing, we remind you that the company and its management are responsible for the $\,$

accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or

absence of action by the staff.

You may contact Christine Torney at 202-551-3652 or Mary Mast at 202-551-3613 with any questions.

Sincerely,

Division of

Corporation Finance

Office of Life

Sciences